Introduction
The breakpoint cluster region (bcr) gene is implicated in the pathogenesis of two human leukemias that are associated with the Philadelphia chromosome. Most chronic myelogenous leukemias (CML), and a subset of the acute lymphocytic leukemias (ALL), can be attributed to the aberrant expression of fusion proteins that encode amino terminal sequences from Bcr and carboxyl terminal sequences from the oncogenic nonreceptor tyrosine kinase Abl (Chan et al., 1987; Clark et al., 1988; Fainstein et al., 1987; Konopka et al., 1984; Kurzrock et al., 1987; Walker et al., 1987) . Although animal models suggest that elevated levels of Abl tyrosine kinase activity contribute to Bcr-Abl mediated leukemogenesis (Lugo et al., 1990) , the residues that distinguish the rearrangements associated with ALL (p185 Bcr-Abl) from the rearrangements associated with CML (p210 Bcr-Abl) reside within the Bcr protein. Thus, a complete understanding of the biological mechanisms that distinguish ALL from CML may depend upon the characterization of the signaling activities that reside within Bcr.
The major product of the bcr gene is a 160 kD protein that exists predominantly as a 600 kD oligomer (McWhirter et al., 1993) . Oligomerization is mediated by an amino terminal coiled coil domain (residues 1 -40) that is required for the transforming activity of Bcr-Abl chimerics. Four additional structural domains have been identified within the Bcr protein. Contained within the amino terminus of Bcr (residues 1 -414) is a serine/threonine kinase activity that when expressed alone, or within the context of the full-length protein, exhibits both autophosphorylation and transphosphorylation activity (Maru and Witte, 1991) . The central portion of Bcr (residues 501 -870) consists of a tandem DH/PH domain (Ron et al., 1991) that is shared by all members of the Rho specific guanine nucleotide exchange factors (RhoGEFs) (Whitehead et al., 1997) . RhoGEFs have been shown to activate members of the Rho family of small GTPases by catalyzing the exchange of GDP for GTP. In in vitro assays, the isolated DH/PH domain of Bcr has been shown to catalyze exchange of GDP for GTP on the Rho family members RhoA, Cdc42 and Rac1 (Chuang et al., 1995) . The carboxyl terminus of Bcr (residues 1172 -1271) contains a GTPase activating protein (GAP) activity that is also specific for members of the Rho family (Diekmann et al., 1991) . GAPs stimulate the intrinsic rate of hydrolysis of GTPases, thus converting them to the inactive GDP-bound form. Bcr-mediated GAP activity has been demonstrated for Rac1, Rac2 and Cdc42 in vitro (Chuang et al., 1995; Diekmann et al., 1991) , and Bcr-null mutant mice exhibit phenotypes that are consistent with elevated levels of activated Rac (Voncken et al., 1995) . Also contained within the carboxyl terminus of Bcr (residues 911 -1036) is a C2 domain. Such domains have been described in over 100 mammalian proteins (including other GAPs) and have been shown to bind phospholipids in a calcium dependent manner (Rizo and Sudhof, 1998) . The C2 domain of Bcr has not been characterized and its function is not currently known.
The presence of the DH/PH module within Bcr is of particular interest since many RhoGEFs have been isolated based on their oncogenic activity, and in several instances, this activity has been mapped to this tandem structure (Whitehead et al., 1997) . Although this domain is present in both p160 Bcr and p210 Bcr-Abl, no in vivo functions have been attributed to it in either context. However, the recent observation that the DH/PH domain of p210 Bcr-Abl cannot be functionally replaced with homologous sequences from Cdc24 (a related RhoGEF), or with irrelevant sequences of equivalent size (Kin et al., 2001) , suggests that these sequences may in fact contain transforming potential, which would be consistent with what has been observed for multiple members of the RhoGEF family (Whitehead et al., 1997) .
It is generally thought that RhoGEFs regulate proliferative signaling pathways through the aberrant activation of their GTPase substrates, several of which have also been demonstrated to possess oncogenic potential (Whitehead et al., 1997) . However, the downstream signaling events that are triggered by chronic stimulation of Rho family GTPases, and which contribute to RhoGEF transformation, are still somewhat obscure. Rho controlled signaling pathways have been shown to regulate multiple cellular behaviors including reorganization of the actin cytoskeleton (Hall, 1994; Nobes and Hall, 1995; Ridley, 1995) , regulation of the cell cycle (Olson et al., 1995) and the activation of multiple transcription factors including Elk-1, c-Jun, SRF and NF-kB (Coso et al., 1995; Hill et al., 1995; Minden et al., 1995; Perona et al., 1997) . This diversity of biological activity can be explained by the large, and equally diverse, collection of effector molecules that bind to activated Rho family GTPases (Zohn et al., 1998) . Recent reports have implicated several of these effectors in Rho and RhoGEF mediated transformation. A pharmacological inhibitor that has been reported to be specific for the RhoA effector protein ROCK, can efficiently block the transforming activity of RhoA, Dbl and Net1, in NIH3T3 cells (Sahai et al., 1999) . ROCK has been implicated in Rho-mediated assembly of focal adhesion complexes (Amano et al., 1997; Ishizaki et al., 1997; Leung et al., 1996; Watanabe et al., 1999) . A genetic inhibitor that blocks activation of c-Jun by RhoA has also been shown to block RhoA-mediated transformation. RhoA activation of c-Jun is thought to occur through a second effector protein, PKN (Marinissen et al., 2001) . Finally, genetic inhibitors that block transcription by NF-kB in NIH3T3 cells are potent inhibitors of Dbl and Dbs transformation in the same cell type . Although the effector protein responsible for Rho-mediated activation of NF-kB has not yet been identified, NF-kB contributes to the transforming activity of many oncogenes including Bcr-Abl (Reuther et al., 1998) .
Since RhoGEF domains often exhibit potent signaling and transforming activities, we wished to determine whether the Bcr-encoded sequences have similar properties. In the current study we have determined that expression of the isolated DH/PH domain of Bcr is associated with the activation of Cdc42 (but not Rac1 or RhoA) in vivo, and is associated with potent stimulation of NF-kB response elements. Both activities are suppressed by carboxyl-and amino-proximal flanking sequences when expressed in cis or in trans. Activation of NF-kB by Bcr is not associated with nuclear translocation, but rather with p38 MAPKdependent transactivation of p65/RelA. This activity occurs independently of Cdc42 suggesting that Bcr may utilize additional GTPase targets in vivo. These observations constitute direct evidence that the DH/ PH domain of Bcr can exhibit independent signaling activity in vivo, and raises the possibility that such activity may influence Philadelphia chromosome positive leukemias.
Results

Activation of NF-kB response elements by the isolated DH/PH domain of Bcr
We have shown previously that many RhoGEFs share a common ability to stimulate signaling pathways that result in the activation of multiple transcription factors (Westwick et al., 1998; Whitehead et al., 1999) . In all cases that have been examined, this activity has been mapped to the conserved DH/PH domain module. We wished to determine whether such in vivo activity also resides within the DH/PH domain of Bcr. Towards this end, a panel of Bcr truncation mutants was constructed (Figure 1a ), all of which contain the DH/PH domain (residues 491 -876) along with varying amounts of flanking sequence. All members of the panel were fused to an HA epitope, and expression was confirmed in COS-7 cells by Western blot with an anti-HA antibody (F7, Santa Cruz Biotechnology, Santa Cruz, CA, USA; Figure 1b ). In each case a cross-reactive band was identified that corresponded in size to the predicted translation product of the various derivatives.
In order to determine whether expression of the Bcr panel corresponded with increased activity on transcriptional response elements, each panel member was co-transfected with a luciferase-based reporter plasmid that was designed to measure either NF-kB-, Serum response factor (SRF-), or c-Jun-mediated promoter activity. Although transient expression of the isolated DH/PH domain of Bcr (Bcr(491 -876)) was associated with activation of the NF-kB response element in COS-7 cells (Figure 2a ), and to a lesser extent in NIH3T3 cells (Figure 2b) , very weak or no activation was observed with all other panel members (complete data for NIH3T3 cells is not shown). This suggests that the NF-kB signaling activity is regulated by sequences located either carboxyl or amino proximal to the DH/ PH domain. All members of the panel, including Bcr(491 -876), failed to activate the c-Jun or SRF reporters (data not shown) suggesting that the activation of NF-kB by Bcr is highly specific. Although activation of NF-kB by the DH/PH domain of Bcr is consistent with what we have observed for several other RhoGEFs , the strength of this activation coupled with the failure to activate other response elements constitutes a novel signaling profile within the family.
Inhibition of NF-kB activity by expression of flanking sequences in trans
To confirm that the DH/PH domain of Bcr is flanked by inhibitory sequences, additional epitope-tagged derivatives were constructed that encoded these putative inhibitory domains (Figure 3a; and Bcr(876 -1163)). As an additional control, a construct was made that encoded the isolated kinase domain (Bcr (1 -413) ). Expression of all three constructs was verified by transient transfection and Western blot analysis in COS-7 cells (Figure 3b ). Initially we tested each derivative for their ability to regulate endogenous NF-kB activity (Figure 3c ). The two domains that we had identified as containing inhibitory sequences failed to have any effect on endogenous NF-kB activity suggesting that they are incapable of independently influencing the reporter element. In contrast, a genetic inhibitor that can specifically block NF-kB nuclear translocation (IkBa(SS)), reduced the basal level of activity on this reporter element by 81%. Surprisingly, the amino terminal kinase domain also exhibited a modest yet reproducible activation of the NF-kB reporter (threefold) suggesting that Bcr can regulate NF-kB activation via multiple, independent mechanisms.
Next we wished to determine whether the two inhibitory domains could block NF-kB activation by Bcr when expressed in trans. Co-expression of either or Bcr(876 -1163) with the isolated DH/ PH domain module resulted in decreased activation of the NF-kB reporter (Figure 3d, 24 and 60% respectively) . This suggests that each domain may be able to form independent inhibitory complexes with the isolated GEF domain. The isolated kinase domain did not exhibit any inhibition relative to vector controls thus confirming the specificity of the inhibition.
To further examine the specificity of the Bcr-encoded inhibitory domains we also determined whether each of the isolated domains could block activation of the NFkB reporter by a second RhoGEF. We have shown previously that a derivative of Dbl that contains the isolated DH/PH domain (Dbl-HA1) is a strong Figure 1 Structure and expression of truncated derivatives of human Bcr. (a) The domain structure of the full-length Bcr protein is illustrated in the upper line (O, oligomerization domain; kinase, serine/threonine kinase domain; DH, Dbl-homology domain; PH, pleckstrin homology domain; C2, calcium-binding motif; GAP, GTPase activating protein domain) and the bars below indicate the regions of the protein included in predicted translation products of the various cDNA derivatives. cDNA designations indicate the amino acid residues from Bcr that are contained within the translation product. All derivatives are fused, at either the amino or carboxyl terminus (as indicated), to an in-frame epitope from the hemagglutinin protein (HA) of influenza virus. (b) All cDNA derivatives were cloned into the pAX142 mammalian expression vector, transiently expressed in COS-7 cells, and detected by Western blot using a mouse anti-HA monoclonal antibody (F-7, Santa Cruz Biotechnology, Santa Cruz, CA, USA) Figure 2 Activation of an NF-kB responsive promoter element by the DH/PH domain module of Bcr. COS-7 cells (a) or NIH3T3 cells (b) were transiently transfected with 3 mg of pAX142 (vector) or pAX142 containing the indicated Bcr derivatives along with a luciferase reporter plasmid to determine stimulation of NF-kB-mediated transcriptional activity (NF-kB-luc), and pCMVnlac (0.25 mg) as an internal control for transfection efficiency and/or growth inhibition. Luciferase and b-galactosidase activity was measured and expressed as fold activation relative to the level of activation seen with the vector control. Luciferase activity was then standardized relative to b-galactosidase activity. Data shown are representative of at least three independent assays performed on duplicate plates. The error bars indicate standard deviations activator of NF-kB response elements in NIH3T3 cells . A similar activation was observed when we expressed this construct alone in COS-7 cells (Figure 3e ). Co-expression with the amino terminal inhibitory domain of Bcr (Brc(415 -490)) substantially reduced the activation of the reporter by Dbl (79%) suggesting that this domain may be promiscuous in its ability to form inhibitory complexes with DH/PH domains. No significant inhibition was observed when Dbl was co-expressed with the isolated kinase domain, or with the carboxyl-terminal inhibitory domain.
The in vivo GEF activity of the Bcr DH/PH domain is inhibited by flanking sequences Our observation that the expression of the flanking sequences of the Bcr DH/PH domain can inhibit Bcrmediated signaling in trans suggests that these sequences may directly regulate the GEF activity residing within Bcr. We wished to confirm this hypothesis in vivo. It has been shown previously that the isolated DH/PH domain of Bcr contains GEF activity for the Rho family members RhoA, Rac1 and Cdc42 in vitro (Chuang et al., 1995) . To determine whether this observation could be recapitulated in vivo, we measured levels of RhoA-GTP, Cdc42-GTP and Rac1-GTP in COS-7 cells that were transiently transfected with full-length Bcr (Bcr(1 -1271)) and the isolated DH/PH domain (Bcr(491 -876)) (Figure 4a c). For comparison we also transfected a transforming derivative of Dbl (Dbl-HA1), which has in vitro exchange activity for RhoA and Cdc42. Constitutively activated mutants of RhoA, Rac1 and Cdc42 that are locked in the GTP-bound state (RhoA(63L), Rac1(61L) and Cdc42(12V)) served as positive controls. Although we were able to affinity purify the constitutively activated GTPases out of COS-7 cell lysates, we were unable to detect any differences in endogenous Cdc42-GTP, RhoA-GTP or Rac1-GTP levels between the vector and the Bcr lysates. Dbl-HA1 was able to activate endogenous RhoA in COS-7 cells, Figure 3 The DH/PH domain of Bcr is regulated by flanking sequences. (a) The domain structure of the full-length Bcr protein is indicated in the upper line (see Figure 1 for explanation of abbreviations) and the bars below indicate the regions of the protein included in predicted translation products of the various cDNA derivatives. cDNA designations indicate the amino acid residues from Bcr that are contained within the translation products. All derivatives are fused to an in-frame epitope, at either the amino or carboxyl terminus (as indicated), from the hemagglutinin protein (HA) of influenza virus. (b) All derivatives were cloned into pAX142, transiently expressed in COS-7 cells, and detected by Western blot using a mouse anti-HA monoclonal antibody (F-7, Santa Cruz Biotechnology, Santa Cruz, CA, USA). (c -e) COS-7 cells were transiently transfected with 3 mg of pAX142, or pAX142 containing the indicated cDNA derivatives, along with NF-kB-luc and pCMVnlac. For c, relative luciferase units are expressed as a percentage relative to the number of units seen with vector controls. For d and e, data are calculated and presented as in Figure 2 Activation of NF-kB by Bcr M Korus et al but not Rac1 or Cdc42. The failure of Bcr to activate RhoA, Rac1 or Cdc42 could not be attributed to poor expression of Bcr in the lysates (Figure 4d ). If we increased the endogenous pool of GTPases by co-transfecting Bcr with cDNAs that encode wild-type versions of RhoA, Rac1 or Cdc42, we were able to detect elevated Cdc42-GTP in the Bcr-transfected cells (Figure 4e ), but not elevated RhoA or Rac1 (not shown). The level of activity was equivalent to what we observed with the transforming derivative of Dbl and was only observed with the isolated DH/PH domain of Bcr. Thus, although the DH/PH domain of Bcr appears competent to catalyze exchange when expressed in COS-7 cells, it does not appear to regulate endogenous steady state levels of RhoA, Rac1 or Cdc42.
To determine whether the inhibitory flanking sequences of the Bcr DH/PH domain could diminish the Cdc42 specific GEF activity, we measured Cdc42-GTP loading in COS-7 cells that were transiently cotransfected with Bcr(415 -876) or Bcr(491 -1162) and wild-type Cdc42 (Figure 4f ). Although both of these Figure 4 The in vivo GEF activity of Bcr is regulated by flanking sequences. COS-7 cells were transiently transfected with 3 mg pAX142 (vector) or pAX142 that contained the indicated cDNAs. Lysates were collected at 48 h and aliquots were examined by Western blot for expression of RhoA (a: Total-RhoA), Cdc42 (b: Total-Cdc42), Rac1 (c: Total-Rac1) and the HA-tagged Dbl and Bcr derivatives (d: anti-HA). The remainder of the lysates were then split into three parts, each of which was normalized for expression of either RhoA, Rac1 or Cdc42. Each lysate was then subjected to affinity purification using immobilized GSTPak (Rac1 and Cdc42) or GST-C21 (RhoA). GTP-bound Cdc42 (b: GTP-Cdc42) and Rac1 (c: GTP-Rac1) that were precipitated with GST-PAK, or GTP-bound RhoA (a: GTP-RhoA) that was precipitated with GST-C21, were visualized by Western blot. Additional lysates were prepared from cells that were transfected with constitutively activated versions of the relevant GTPases (either RhoA(63L), Rac1(61L) or Cdc42(12V)) as indicated. These lysates were also subjected to affinity purification with the relevant GST fusion protein and were included as positive controls. (e, f) COS-7 cells were transiently co-transfected with the indicated plasmids along with a plasmid that encodes wild-type Cdc42. Lysates were collected at 48 h and affinity purifications were performed as described. GTP-Cdc42 and Total-Cdc42 levels were determined by phosphoimage analysis. Each value was first normalized to the vector control, and then GTP-Cdc42 levels were further normalized relative to Total-Cdc42 levels. All experiments were performed a minimum of three times and data shown constitutes a representative data set Activation of NF-kB by Bcr M Korus et al derivatives were expressed at comparable levels to the isolated DH/PH domain neither was able to induce an increase in Cdc42-GTP loading. Thus, the GEF activity that resides within Bcr appears to be under autoinhibitory control that is mediated by residues located within flanking domains.
Bcr activates NF-kB through a Cdc42-independent mechanism
Since activated derivatives of Cdc42 have been shown to stimulate transcription from NF-kB responsive reporters in COS-7 cells (Montaner et al., 1998; Perona et al., 1997) , and the isolated DH/PH domain of Bcr can activate both Cdc42 and NF-kB response element in this same cell type, we wondered whether Bcr activates NF-kB in a Cdc42-dependent manner. It is possible that endogenous Cdc42 is cycling more rapidly in the Bcr transfected cells, and that this increased cycling is not reflected in discernible increases in steady-state levels of Cdc42-GTP. To explore this possibility further, we wished to determine if Bcr stimulation of transcription from the NF-kB reporter is impaired by co-expression with specific inhibitors of Cdc42 function. pAX142-cdc42(17N) encodes a GTPase defective dominant-inhibitory mutant of Cdc42 that has been used extensively to analyse Cdc42-mediated signaling activities. pyDF30-WASP-GBD encodes the GBD of WASP (an effector protein specific for Cdc42) and has been shown to specifically inhibit Cdc42 mediated functions. Co-expression of Bcr with Cdc42(17N) failed to block activation of the NFkB reporter while co-expression with wild-type Cdc42 produced levels of activation that are more consistent with additivity than with synergy ( Figure 5a) . Similarly, WASP-GBD failed to block reporter activation by Bcr but did block activation of the same reporter by an activated derivative of Cdc42(12V); Figure 5b ). Collectively, these observations would suggest that activation of NF-kB reporters by Bcr cannot be accounted for by activation of endogenous Cdc42 in COS-7 cells.
Activation of the NF-kB response element by Bcr is mediated by nuclear NF-kB Despite our inability to identify the in vivo substrate for Bcr in COS-7 cells, we wished to further explore the mechanism through which Bcr was stimulating NF-kB activation. The canonical mechanism of NF-kB activation is through its dissociation from the regulatory IkB molecules (Karin, 1999) . In response to extracellular stimuli such as IL-1 or TNFa, IkB becomes phosphorylated and targeted for degradation by ubiquitin-mediated proteolysis. IkB phosphorylation is mediated by the IkB kinase (IKK) complex, a heterodimeric kinase whose catalytic core is comprised of IKKa and IKKb. Upon release from IkB, NF-kB is free to translocate to the nucleus where it can bind to NF-kB responsive elements. Several genetic inhibitors have been described that can block IkB phosphorylation and reduce the nuclear pool of NF-kB. IkBa(SS) is a derivative of IkBa that has been mutated on serines 32 and 36. This mutant cannot be phosphorylated by the IKK complex and forms irreversible complexes with NF-kB in the cytoplasm. To determine whether activation of the NF-kB response element by Bcr is mediated by the nuclear pool of NF-kB, we cotransfected Bcr(491 -876) with an expression plasmid that contains IkBa(SS) (Figure 6a ). In the presence of the NF-kB inhibitor, activation of the reporter by Bcr was dramatically reduced (88%). Importantly, this reagent was also effective in blocking endogenous activity at the NF-kB reporter (Figure 3c) suggesting that a nuclear pool of transcriptionally active NF-kB is present within COS-7 cells in the absence of Bcr expression.
Activation of the NF-kB response element by Bcr is not associated with increased nuclear translocation Our observation that Bcr activation of NF-kB response elements can be blocked by IkBa(SS) suggests that Bcr may regulate the nuclear accumulation of NF-kB. Upon release from IkB, NF-kB is free to translocate to the nucleus where it can bind to NF-kB responsive elements. This event that can be detected using electrophoretic mobility shift assays (EMSA). Using such an assay we were unable to detect increased nuclear translocation of NF-kB in COS-7 cells transfected with either the isolated DH/PH domain, or full-length Bcr (Figure 6b ). In contrast, treatment of the cells with TNFa for 30 min prior to harvesting the Figure 5 Bcr activates NF-kB through a Cdc42-independent mechanism. COS-7 cells were transiently transfected with 3 mg of pAX142 and/or pAX142 containing the indicated cDNAs, along with NF-kB-luc and pCMVnlac. Data are calculated and presented as in Figure 2 Activation of NF-kB by Bcr M Korus et al lysates was associated with a measurable increase in the nuclear pool of the transcriptionally active p50/p65 heterodimer. The identities of the NF-kB complexes were confirmed using competition and supershift assays (data not shown). To explore the possibility that TNFa may be a more robust activator of NF-kB than Bcr, and that our failure to detect nuclear translocation in response to Bcr expression reflects a lack of sensitivity of the EMSA, we compared TNFa and Bcr in their ability to activate the NF-kB reporter. Regardless of the duration of time during which we exposed COS-7 cells to TNFa prior to harvesting the lysates, we were unable to detect a level of activation equivalent to that seen with Bcr ( Figure 6c) . Thus, our analysis would suggest that the activation of NF-kB by Bcr is mechanistically distinct from that seen with TNFa, and not associated with any readily discernible increase in nuclear translocation.
Bcr activates the transactivation domain of RelA/p65
Despite the apparent lack of nuclear accumulation of NF-kB in Bcr transfected cells, activation of NF-kB response elements is observed. One possibility is that Bcr is exerting its influence on a preexisting nuclear pool of NF-kB. Thus, expressing IkBa(SS) would clear the nucleus of this pool and reduce the number of targets for Bcr activation. It has been shown previously that a second mechanism of NF-kB activation can occur involving phosphorylation of the RelA/p65 transactivation domain. Such a mechanism has been observed for activation of NF-kB by Ras, Bcr-Abl and Akt. To determine whether Bcr utilizes a similar mechanism to activate NF-kB, we co-transfected COS-7 ( Figure 7a ) and NIH3T3 ( Figure 7b ) cells with Bcr(491 -876), and with a luciferase reporter construct fused to a promoter containing five Gal4 DNA-binding sites (Gal-luc) along with expression constructs encoding the Gal4 DNA-binding domain fused to transactivation domain 1 (TA1) of RelA/p65. This reporter system was designed to detect modifications at the transactivation domain of RelA/p65. Transient expression of Bcr(491 -876), but not full-length Bcr, activates the transcriptional function of Gal4-p65 in both NIH3T3 and COS-7 cells. Interestingly, TNFa, which is a potent stimulator of the NF-kB-luc reporter (Figures 6c and 7a ), failed to activate the Gal4-p65 reporter in COS-7 cells. This further suggests that TNFa and Bcr activate NF-kB by distinct mechanisms and supports a model in which Bcr activates NF-kB by modification of the transactivation domain of p65/ RelA.
Bcr activates NF-kB through a p38 MAPK-dependent mechanism
Previous studies have shown that p38 MAPK can stimulate the transcriptional activity of NF-kB through a mechanism that does not require nuclear accumulation (Bergmann et al., 1998; Madrid et al., 2001; Wesselborg et al., 1997) . Additionally, we have shown previously that many RhoGEFs share a common ability to activate p38 MAPK in COS-7 cells (Westwick et al., 1998) . To determine whether Bcr activates NF-kB through a p38 MAPK-dependent mechanism, we measured Bcr activation of the NF- . All lysates except lane 1 were incubated with a radiolabeled oligonucleotide probe containing an NF-kB binding site, and resolved on 5% polyacrylamide gels. NF-kB complexes were identified through competition and supershift assays (not shown) and are indicated with arrows. (c) COS-7 cells were transfected with 3 mg pAX142 or pAX142-bcr(491 -876), or were treated with 10 ng/ml TNFa for the indicated time period prior to harvesting lysates. Media was changed and fresh TNFa added every 3 h as required. NF-kB-luc and pCMVnlac were included in each transfection. Data are calculated and presented as in Figure 2 Activation of NF-kB by Bcr M Korus et al kB-luc and Gal4-p65 reporters in the presence or absence of a highly specific pharmacological inhibitor of p38 MAPK (SB203580). Our initial examination of cell lysates revealed elevated levels of activated p38 MAPK (Figure 8a ) in the Bcr-transfected cells, which was not observed in control cells, or in the presence of the inhibitor. This suggests that Bcr can activate endogenous p38 MAPK, and that the inhibitor can block this activation. Next we determined the effects of the inhibitor on NF-kB activation. In the presence of the inhibitor, activation of both the NF-kB-luc and Gal4-p65 reporters by Bcr was substantially reduced (82 and 69% respectively) relative to controls ( Figure  8b ). Since the concentration of inhibitor that we used is extremely low (400 nM) the effect that we observed is not likely to be due to non-specific activity. Nonspecific activity has only been observed with this inhibitor at concentrations in the 3 -5 mM range (Lali et al., 2000) . These results suggest that Bcr regulates NF-kB through its ability to stimulate endogenous p38 MAPK.
Discussion
The RhoGEF family consists of a large collection of structurally diverse proteins that share a common DH/ PH domain tandem motif (Whitehead et al., 1997) . Numerous studies have now established that the DH domain mediates Rho protein binding and GEF catalytic activity while the PH domain is required for appropriate subcellular localization. Both domains contribute to the potent transforming activity that is associated with activated derivatives of many RhoGEFs (Whitehead et al., 1997) . When expressed in their activated forms, RhoGEFs will stimulate multiple signaling pathways, some of which contribute to cellular transformation (Westwick et al., 1998; Whitehead et al., 1999) . These include activation of MEK MAPKK and the NF-kB transcription factor. Although Bcr encodes a canonical DH/PH domain motif, with demonstrated GEF activity in vitro (Chuang et al., 1995) , little is known about the fate of this activity within the context of the full-length protein, or within the context of an in vivo system. Such an analysis would be prerequisite to understanding the contribution of these sequences to the transforming activity associated with the human oncogene p210 Bcr-Abl. Our observation that this domain can trigger p38 MAPK-dependent NF-kB transcriptional activity in vivo, is in accordance with what has been observed for other members of the RhoGEF family , and suggests that this domain can establish productive interactions with GTPase substrates in vivo. Consistent with this, we were able to observe elevated levels of Cdc42-GTP in Bcr-transfected cells.
Our finding that the signaling activity associated with the Bcr DH/PH domain is subject to autoinhibitory control is also consistent with findings from other family members. Autoinhibition as a mechanism of GEF regulation has been invoked for many RhoGEFs including Dbl, Vav, Ost, Ect2 and Tiam1 (Aghazadeh et al., 2000; Habets et al., 1994; Horii et al., 1994; Miki et al., 1993; Ron et al., 1991) . RhoGEFs generally exist in a quiescent state and require activation to exhibit signaling and transforming activity. The mechanisms of activation are diverse and include interaction with upstream signals such as phosphoinositides, Ga subunits of heterotrimeric G proteins, and protein kinases. Often such signals appear to relieve intramolecular constraints upon GEF activity converting RhoGEFs to an active state. For example, the amino terminal sequences of the Vav protein bind to the DH domain active site blocking access to GTPase substrates (Aghazadeh et al., 2000) . Phosphorylation Figure 7 Bcr activates the transactivation domain of RelA/p65. COS-7 cells (a) or NIH3T3 cells (b) were either treated with TNFa (10 ng/ml for 24 h prior to lysate collection), or were transfected with plasmids encoding the indicated Bcr derivatives (3 mg), along with either NF-kB-luc or expression vectors for the Gal4 DNA binding domain fused to transactivation domain 1 of p65 (0.25 mg Gal-p65) and a Gal4 luciferase reporter (2.5 mg Gal4-luc). For each condition, pCMVnlac was also included in the transfection. Data are calculated and presented as in Figure 2 of Vav on tyr-174 (which is contained within these inhibitory sequences) by Lck, or removal of these amino-terminal sequences by truncation, exposes the oncogenic potential of the protein (Han et al., 1997) . Similarly, autoinhibitory sequences have been identified within the amino terminus of the Dbl protein that bind directly to the PH domain blocking access to GTPase substrates and masking the intracellular targeting function of the PH domain (Bi et al., 2001) . Removal of this flanking sequence by truncation is necessary to expose the Dbl encoded exchange and transforming activity. The mechanisms through which the catalytic activities of full-length natively expressed RhoGEFs such as Dbl and Bcr are regulated remains to be determined.
Our observation that the two autoinhibitory domains that we have identified within the Bcr protein can block signaling when expressed in trans, leads us to speculate that residues contained within these domains can form direct contacts with the DH/PH domain. This is supported by our observation that these domains can individually block Bcr-mediated activity in vivo. The amino-terminal inhibitory domain (residues 415 -490) has no obvious similarities with other proteins and contains no known motifs. Structural data on the folding of this domain relative to the GEF core may be required to gain further insights into the molecular basis of this inhibition. Interestingly, the carboxyl terminal inhibitory domain (residues 876 -1163) contains a C2 domain (residues 911 -1036). Such domains have been described in numerous signaling molecules and are thought to regulate phospholipid binding in a calcium-dependent manner (Rizo and Sudhof, 1998) . Although the function of the C2 domain in Bcr is not known, this domain appears to be necessary for Bcr-mediated GAP activity in vivo (IP Whitehead, unpublished observations) and may function as membrane localization signal that facilitates interactions between Bcr and its in vivo target Rac1. If so, the C2 domain may compete with the PH domain for cellular localization of Bcr, thus preventing Bcr from associating with other GTPase substrates such as Cdc42. However, our observation that expression of this domain can block signaling by Bcr when expressed in trans suggests that this domain may also contain residues that form direct contacts with the DH/PH domain module.
Although experiments using a bacterially purified DH/PH domain module of Bcr have revealed a relatively promiscuous GEF activity in vitro (RhoA, Rac1 and Cdc42) (Chuang et al., 1995) , we have been unable to completely recapitulate these observations in live cells. We have detected increased levels of GTPCdc42 in cells transfected with Bcr, but we have been unable to observe any change in levels of GTP-RhoA or GTP-Rac1. We have observed similar incongruities when comparing the in vivo and in vitro GEF specificities of the Dbs protein in NIH3T3 cells (IPW, unpublished data) . This suggests that cellular context may be the critical determinant of GEF specificity and that in vitro data may not be a reliable predictor of in vivo function. Our observation that genetic inhibitors of Cdc42 function fail to block Bcr-mediated signaling activity further suggests that all the GTPase substrates for Bcr have not yet been identified.
Bcr joins a growing list of signaling molecules that have been shown to activate NF-kB through a mechanism that does not require increased nuclear accumulation or DNA binding. Recent studies on cell lines derived from T2K and GSK-3 knockout mice have suggested that this is a physiologically relevant mechanism of NF-kB activation (Bonnard et al., 2000; Hoeflich et al., 2000) . These cell lines are competent in the nuclear translocation of NF-kB but are completely Figure 8 Bcr activates NF-kB through a p38 MAPK-dependent mechanism. COS-7 cells were transiently transfected with 3 mg pAX142 or pAX142-bcr(491 -876), along with either NF-kB-luc (2.5 mg), or Gal-p65 (0.25 mg) and Gal4-luc (2.5 mg). For each condition pCMVnlac was included in the transfection. Three hours prior to lysate collection, SB203580 (400 nM) or water (control) was added to the media. Lysates were collected at 48 h and were analysed by Western blot to determine endogenous levels of total (C-20, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and phosphorylated (9211-CST, New England Biolabs, Beverly, MA, USA) p38MAPK (a), or for luciferase activity (b). Data are calculated and presented as in Figure 2 Activation of NF-kB by Bcr M Korus et al defective in any transactivation function. A series of recent studies has begun to assemble the components of a signaling pathway that may contribute to RelA/ p65 phosphorylation and transactivation (Finco et al., 1997; Madrid et al., 2001; Sizemore et al., 1999) . IL-1b, Ras and Akt have been shown to stimulate the transactivation function of RelA/p65, with activation by IL-1b occurring in an Akt-dependent manner (Sizemore et al., 1999) . In turn, Akt has been shown to stimulate the transactivation function of RelA/p65 in an IkBb and p38 MAPK-dependent manner (Madrid et al., 2001) . Although the mechanism(s) through which either IKKb or p38 MAPK cause phosphorylation of p65 remains unclear, our observation that Bcr activation of NF-kB is dependent on p38 MAPK function, suggests that Bcr may be stimulating NF-kB in a manner that is either similar to or dependent upon Akt. We are currently exploring this possibility.
The presence of the Bcr DH/PH domain within the p210 Bcr-Abl chimeric protein raises the possibility that it may contribute to Bcr-Abl-mediated oncogenesis. However, there is conflicting evidence concerning the role of the Bcr encoded DH/PH domain in transformation. The transforming potential of p185 Bcr-Abl, which lacks the DH/PH domain, is stronger than that of p210 Bcr-Abl suggesting that this domain may inhibit transformation. However, there have been several recent studies that suggest that this may not be the case. First, replacement of the DH domain of Bcr with a homologous domain from Cdc24, or with irrelevant sequences, diminishes transforming activity in Rat1 cells (Kin et al., 2001) . This suggests that p185 Bcr-Abl and p210 Bcr-Abl may possess distinct transforming properties, and that the DH/PH domain may perform a specific function within the context of p210. Second, this domain has been reported to activate Rac1 in vitro (Chuang et al., 1995; Diekmann et al., 1991) , and dominant negative Rac1 blocks BcrAbl transformation (Skorski et al., 1998) . Finally, xeroderma pigmentosum group B protein (XPB), which is a helicase of the basal class II transcription factor H (TFIIH), binds to the DH domain in the context of Bcr-Abl (Maru et al., 1999) . This interaction reduces the helicase and ATPase activities of XPB and reduces its repair activity in rodent models. Since progression of CML from the chronic to acute phases is associated with genetic instability, it has been proposed that BcrAbl may confer a mutator phenotype via its inactivation of XPB (Maru, 2001) .
We have shown previously that NF-kB activation contributes to the transforming potential of several RhoGEFs , and others have shown that NF-kB is required for Bcr-Abl-mediated transforming activity (Reuther et al., 1998) . However, activation of NF-kB by Bcr-Abl in 32D cells has been attributed to the Abl encoded tyrosine kinase activity and a p210 Bcr-Abl derivative that lacks tyrosine kinase activity is not able to activate NF-kB-dependent response elements (Reuther et al., 1998) . The failure of this mutant to activate NF-kB may reflect the presence of the amino-terminal inhibitory domain that we have identified within Bcr, or may reflect the absence of specific co-factors in the 32D cell line that are required for activation of the Bcr encoded GEF activity. Nonetheless, our observation that both the DH/PH domain and the amino-terminal serine/threonine kinase domain of Bcr can activate a signaling pathway that has demonstrated roles in tumorigenesis suggests that these activities need to be examined in greater detail in the context of the Bcr-Abl oncogenes.
Materials and methods
Molecular constructs
The pAX142 mammalian expression vector has been described previously (Whitehead et al., 1995) . pAX142-bcr(1 -1271), pAX142-bcr(1 -876), pAX142-bcr(415 -876), pAX142-bcr(491 -876), pAX142-bcr(491 -1163), pAX142-bcr(491 -1271), pAX142-bcr(1 -413), pAX142-bcr(415 -490), and pAX142-bcr(876 -1163) contain cDNAs that encode the indicated amino acids of the human Bcr protein fused to an HA epitope tag. All PCR products that were used in the synthesis of these derivatives were sequenced in their entirety. Detailed descriptions of the cloning strategies used to generate each derivative are available upon request.
Construction of pAX142-IkBa(SS), pAX142-cdc42(17N), pAX142-cdc42(12V), pAX142-cdc42(WT), pAX142-rac1(61L), pAX142-rhoA(63L), and pAX142-dbl(HA1) have been described previously . pyDF30-WASP-GBD encodes the GTPase binding domain (GBD) of WASP (the product of the Wiskott-Aldrich syndrome locus) and was kindly provided by M Symons (Qiu et al., 1997) .
The reporter constructs utilized in the luciferase-coupled transcriptional assays have been described previously: NFkB-luc contains the luciferase gene under control of a minimal promoter that contains tandem copies of the HIV NF-kB binding sequences (Galang et al., 1996) ; Gal-luc contains the luciferase gene under the control of a promoter that contains five Gal4 DNA-binding sites (Su et al., 1994) ; Gal4-p65 contains the Gal4 DNA-binding domain fused to transactivation domain 1 (TA1) of RelA/p65 (Schmitz and Baeuerle, 1991) . pCMVlac encodes the sequences for the bgalactosidase gene under the control of the CMV promoter (provided by J Samulski).
Cell culture and reagents COS-7 and NIH3T3 cells were maintained in Dulbecco's modified Eagle medium (DMEM; high glucose) supplemented with 10% fetal bovine serum (Sigma, St. Louis, MI, USA) or 10% bovine calf serum (JRH, Lenexa, KS, USA) respectively. The specific p38 MAPK pharmacological inhibitor SB203580 (Calbiochem, San Diego, CA, USA) was used at a working concentration of 400 nM unless otherwise indicated.
Transient expression reporter gene assays
For transient expression reporter assays, cells were transfected by calcium phosphate co-precipitation (NIH3T3) or by DEAE-dextran (COS-7) as described previously (Clark et al., 1995; Whitehead et al., 1995) . Cells were allowed to recover for 30 h, and were then starved in DMEM that was supplemented with 0.5% serum for 14 h before lysate preparation. Analysis of luciferase expression was as described previously with enhanced chemiluminescent reagents and a Monolight 3010 luminometer (Analytical Luminescence, San Diego, CA, USA) (Hauser et al., 1995) . bgalactosidase activity was determined using Lumi-Gal substrate (Lumigen, Southfield, MI, USA) according to the manufacturer's instructions. All assays were performed in triplicate.
Protein expression
Protein expression in transiently transfected COS-7 cells was determined by Western blot analysis as described previously (Whitehead et al., 1995) . Protein was visualized with enhanced chemiluminescence reagents (Amersham Pharmacia, Piscataway, NJ, USA).
Electrophoretic mobility shift assays
Nuclear extracts from COS-7 cells were prepared as follows. Cells were collected, washed three times in cold phosphatebuffered saline, and then gently resuspended in 10 mM HEPES, pH 7.6, 60 mM KCl, 1 mM EDTA, 0.275% NP-40, 1 mM DTT, 2.5 mg/ml aprotinin, 5 mg/ml leupeptin, 2.5 mg/ml pepstatin, 1 mM PMSF (CE Buffer), and then incubated on ice for 3 -4 min. Nuclei were then pelleted at 15 000 r.p.m. for 4 min at 48C, washed with 100 ml of CE buffer lacking NP-40, and then spun again at 15 000 r.p.m. for 4 min at 48C. The supernatant was then removed and replaced with two pellet volumes of 20 mM Tris, pH 8.0, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 25% glycerol, 2.5 mg/ml aprotinin, 5 mg/ml leupeptin, 2.5 mg/ml pepstatin, 0.5 mM PMSF. Salt concentration was adjusted to 400 mM with 5 M NaCl and then incubated on ice for 10 min with vortexing. Nuclear lysates were clarified by centrifugation at 14 000 r.p.m. for 10 min and then glycerol was added to a final concentration of 20%.
g-32 P labeled NF-kB consensus oligonucleotides were prepared using reagents from the Gel Shift Assay System (Promega, Madison, WI, USA) using protocols provided by the manufacturer. Unincorporated nucleotide was removed and per cent incorporation determined using G-25 Sephadex Columns (Boehringer Mannheim, Indianapolis, IN, USA). DNA binding reactions were performed as follows. Three ml of nuclear extract was combined with 4 ml 56 binding buffer (250 mM NaCl, 50 mM Tris, pH 7.7, 50% glycerol, 5 mM DTT, 0.5 M EDTA), 1 ml (2 mg/ml) POLY (dI-dC)-POLY(dIdC) (Amersham Pharmacia, Piscataway, NJ, USA), 15 000 c.p.m. radiolabeled oligonucleotide, and water to 20 ml. Reactions were spun for 5 s, incubated at room temperature for 15 min, and then resolved on a 5% polyacrylamide gel. Gels were dried and exposed to Kodak X-Omat Blue Imaging Film. Supershift assays were performed on anti-p50 and anti-p65 polyclonal antibodies (C-20 and NLS respectively, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Cdc42, Rac1 and RhoA activation assays
The p21 binding domains of Pak3 (Rac1/Cdc42; GST-PBD) or Rhotekin (RhoA; GST-C21) (Reid et al., 1996) were expressed as GST fusions in BL21(DE3) cells and immobilized by binding to glutathione-coupled Sepharose 4B beads (Amersham Pharmacia, Piscataway, NJ, USA). The immobilized Rho binding domains were then used to precipitate activated GTP-bound Rac1, Cdc42 (GST-PBD) or RhoA (GST-C21) from COS-7 cell lysates. Cells were washed in cold phosphate-buffered saline and then lysed in 50 mM Tris-HCl, pH 7.4, 2 mM MgCl 2 , 100 mM NaCl, 10% glycerol, 1% NP-40, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 1 mg/ml aprotinin, and 1 mg/ml PMSF. Cell lysates were then cleared by centrifugation at 10 000 g for 10 min at 48C. The expression of proteins was confirmed by Western blotting prior to affinity purification. Lysates used for affinity purification were normalized for endogenous Rho levels. Affinity purifications were carried out at 48C for 1 h, washed three times in an excess of lysis buffer, and then analysed by Western blot. Cdc42, RhoA and Rac1 were detected by the B-8 and 26C4 monoclonal, and C-14 polyclonal antibodies respectively (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
